Good question. I wonder if you could move a few indications through under one Phase 1 trial. Its really to assess pk's and adverse effects so there may be some indications that could be grouped I imagine?
If you have safety data from covid phase1, mnd phase1, the old Adelaide hospital cancer phase 1, would we then need a full phase 1 for future indications. I imagine there is a cost element too where a cheaper phase 1 will determine whether you bother with a more costly phase 2.
Ann: Preliminary MPL antiviral leukaemia preclinical WEHI results, page-36
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.015(6.25%) |
Mkt cap ! $109.4M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 22.5¢ | $133.9K | 573.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 303213 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 57592 | 2 |
View Market Depth
| Last trade - 15.46pm 18/10/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |